Trial Profile
An Observer-Blind, Randomized, Controlled Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Male Subjects Aged 10-18 Years.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Hepatitis B vaccine recombinant
- Indications Anal intraepithelial neoplasia; Hepatitis B; Human papillomavirus infections; Penile cancer; Prostatic intraepithelial neoplasia
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 01 Jan 2009 Primary endpoint 'Seroconversion rate' has been met.
- 01 Jan 2009 Results reported in the Journal of Adolescent Health.
- 21 Nov 2006 New trial record.